
What causes colon cancer? And how do you prevent it?
'Colon cancer is the deadliest cancer for men under 50 and second deadliest for women under 50,' says Dr. Heinz-Josef Lenz, professor of medicine at the University of Southern California Keck School of Medicine.
The good news is that when it is caught early, colon cancer is highly treatable. Even better, it's largely preventable through routine screening and healthy dietary and lifestyle habits.
Here's what colon cancer is, what increases your risk and how you can take steps to prevent it.
What is colon cancer?
Colon cancer (also sometimes referred to as colorectal cancer because it often spreads to the rectum) is a disease that begins with the formation of benign polyps in the body's large intestine, also known as the colon. Over time, these polyps can become cancerous (malignant) and spread to other areas of the body.
Symptoms of more advanced stages of colon cancer usually include "abdominal pain, bloody stool, a change in bowel habits (such as constipation or diarrhea), anemia due to blood loss and unexplained weight loss," explains Dr. Xavier Llor, a gastroenterologist at Yale Medicine, who specializes in colon cancer prevention. "But early on," he says, "symptoms can be mild or even absent.'
While individual risk factors vary, the average risk of developing colorectal cancer over one's lifetime is about one in 24 for men and about one in 26 for women, per the American Cancer Society.
In case you missed: James Van Der Beek, Jenna Fischer and the rise of young people getting cancer
What causes colon cancer?
While exact causes can't always be known and vary widely from patient to patient, a family history of colon cancer is known to dramatically increase one's risk, says Llor. Ditto for associated inherited conditions such as Lynch syndrome or familial adenomatous polyposis (FAP). Inflammatory bowel diseases like Crohn's or ulcerative colitis also increase risk due to ongoing inflammation in the digestive tract, explains Lenz, and type 2 diabetes may play a role as well.
Age is a factor, too, as most cases of colon cancer occur in individuals over 50, but incidence among younger adults is rising.
Many of the most common causes of colon cancer are thought to be related to lifestyle behaviors and dietary choices. "Diets rich in red meat such as beef, and pork – particularly if it's fried or broiled – and eating processed meats such as hot dogs and deli meat have been shown to cause colon cancer," says LLor. A lack of physical activity, obesity, smoking and excessive alcohol consumption can also all contribute, says Lenz.
IBD is becoming more common. What exactly causes it?
How to prevent colon cancer
Understanding how these factors can cause colon cancer goes a long way in helping prevent it. But even more people avoid the worst outcomes of colon cancer by getting screened early and as often as is recommended.
Here are the most commonly recommended suggestions that help colon cancer be one of today's most preventable cancers.
No matter how you and your doctor choose for you to get screened, what matters is doing so as soon as you reach the recommended age and then keeping up with screenings every five to 10 years, as advised by your doctor. 'If caught early,' Llor says, 'your chances of surviving colon cancer are excellent at around 90%.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
4 days ago
- Medscape
Mindfulness Therapy Aids IBD Patients With Mental Distress
TOPLINE: Mindfulness-based cognitive therapy reduced psychological distress and improved well-being of patients with inflammatory bowel disease (IBD), and it may offer benefits for sleep quality and inflammation. METHODOLOGY: Even in remission, many patients with IBD experience anxiety, depression, fatigue, and poor sleep, which can lower their quality of life, undermine self-care, and drive up healthcare use. Researchers conducted this trial in the Netherlands between July 2021 and May 2022 to strengthen the evidence for the effectiveness of mindfulness-based cognitive therapy in reducing psychological distress in patients with IBD who had been in remission for at least 3 months and experienced at least mild levels of distress. They randomly assigned 142 patients (mean age, 48.6 years; 64.1% women) to receive either mindfulness therapy plus usual treatment (n = 70; intervention group) or only usual treatment (n = 72; control group); the follow-up period lasted 12 months. The mindfulness therapy program included eight weekly group sessions of 2.5 hours, 30-45 minutes of daily home practice, and a 6-hour silent retreat day between sessions six and seven. Usual treatment included pharmacologic and surgical disease control treatments and the prevention of complications. The primary outcome was psychological distress post-intervention (3 months from baseline), measured using the Hospital Anxiety and Depression Scale (HADS) total score. Secondary outcomes included well-being, sleep, self-compassion, mindfulness skills, and disease activity. TAKEAWAY: Patients in the intervention group vs the control group showed reduced psychological distress (Cohen d [d], -0.61) and an improvement in the HADS total score (unstandardized coefficient B, -3.4; P < .001) at 3 months from baseline. The HADS total scores remained lower in the intervention group vs the control group during the entire 12-month follow-up duration. Compared with patients in the control group, those in the intervention group showed improved well-being (d, 0.41) and increases in mindfulness skills (d, 0.46) and self-compassion (d, 0.42). Patients in the intervention group vs the control group had a reduced total sleep time (d, -0.67) but an increased proportion of deep sleep (d, 0.7). No between-group difference was observed in the occurrence of disease flares, but patients in the control group showed a significant reduction in fecal calprotectin levels, an indicator of intestinal inflammation compared with patients in the control group (d, -0.49). IN PRACTICE: 'Our results demonstrate that MBCT [mindfulness-based cognitive therapy] could be a valuable addition to the currently limited number of psychological treatment options for patients with IBD with psychological distress. The group format of MBCT allows for the simultaneous treatment of more patients, potentially making it more cost-effective than individual therapy. Additionally, group therapy provides opportunities for peer support,' the authors of the study wrote. SOURCE: This study, led by Milou M. ter Avest, MD, Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Nijmegen, the Netherlands, was published online in Inflammatory Bowel Diseases. LIMITATIONS: This study was limited by its unblinded design, risking expectation bias in self-reports. Mindfulness teachers had varied competence levels, which may have introduced bias. The study did not assess sleep disorders such as obstructive sleep apnea, narcolepsy, or restless legs syndrome that may have affected the sleep metrics. Additionally, electroencephalography headbands were not available for all patients, and technical and self-application issues may have led to unusable nights and data loss. DISCLOSURES: This trial was supported by ZonMw (the Netherlands Organisation for Health Research and Development) and the MindMore Foundation. Two authors reported serving on the advisory boards of various pharmaceutical companies, and one of them also reported receiving a grant from Royal DSM. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
4 days ago
- Medscape
Caution Needed in Prescribing IBD Meds in CKD
TOPLINE: Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional therapies, including immunomodulators and aminosalicylates, as well as with JAK inhibitors. METHODOLOGY: From 4%-23% of patients with IBD also have renal disease, which can affect how the body processes medications; however, little data is available to guide physicians in choosing safe and effective IBD treatments for patients with advanced CKD. Researchers conducted a review of studies about IBD treatments in the setting of CKD by searching MEDLINE and EMBASE through March 31, 2025, using relevant keywords. IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators (such as thiopurines and methotrexate), calcineurin inhibitors, biologics (such as monoclonal antibodies against tumor necrosis factors (anti-TNFs), integrin receptors, and interleukins), and small molecules (such as JAK inhibitors and sphingosine-1-phosphate [S1P] receptor modulators). TAKEAWAY: Corticosteroids in advanced kidney disease, including in patients requiring dialysis, do not require dosage adjustment. Budesonide is preferred over prednisolone, and corticosteroids are typically administered at the lowest effective dose for the shortest duration. Mesalazine, an aminosalicylate, can trigger acute interstitial nephritis; the immunomodulator methotrexate, even at 2-4 mg/wk, may cause irreversible renal decline, profound myelosuppression, and higher mortality in patients with end-stage kidney disease on hemodialysis; and calcineurin inhibitors can be nephrotoxic by reducing renal blood flow and glomerular filtration rate. Monoclonal antibodies, including anti-TNF, anti-integrin, and anti-interleukin 12/23 therapies, demonstrated safety in renal insufficiency and hemodialysis. For JAK inhibitors and thiopurines, dose adjustments were recommended in advanced renal disease, whereas S1P receptor modulators could be used in CKD without any dose adjustments. IN PRACTICE: 'Selecting appropriate therapeutics for managing IBD in patients with CKD necessitates a tailored approach, emphasizing diligent surveillance of renal function to optimize treatment efficacy and minimize renal compromise. Dose adjustments of IBD therapeutics are not required for patients with stage I or II CKD. Depending on specific drug metabolism and renal excretion, dose adjustments may be required at more advanced-stage CKD,' the authors wrote. SOURCE: The study, led by Lynna Chen, Eastern Health Clinical School, Monash University in Melbourne, Australia, was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: This review did not discuss limitations. DISCLOSURES: The authors received no specific funding for this work. Two authors disclosed receiving advisory fees and serving as speakers for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
4 days ago
- Yahoo
How much the COVID-19 pandemic aged our brains
NEW HAVEN, Conn. (WTNH) — In today's Health headlines, how much the COVID-19 pandemic aged our brains, the connection between sleep and alcohol consumption in young adults, and how high blood pressure impacts breastfeeding outcomes. Dr. F. Perry Wilson, associate professor at Yale School of Medicine, Yale Medicine physician, and author of 'How Medicine Works and When It Doesn't,' joined Good Morning Connecticut at 9 a.m. to discuss. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.